U.S. PHARMACOPEIA

Search USP29  
Lisinopril Tablets
» Lisinopril Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of C21H31N3O5.
Packaging and storage— Preserve in tight containers.
Identification— The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that of the Standard preparation as obtained in the Assay.
Dissolution, Procedure for a Pooled Sample 711
Medium: 0.1 N hydrochloric acid; 900 mL.
Apparatus 2: 50 rpm.
Time: 30 minutes.
Determine the amount of lisinopril dissolved using the following method.
Mobile phase and Chromatographic system—Prepare as directed in the Assay.
Procedure— Inject a volume of a filtered portion of the solution under test into the chromatograph, record the chromatogram, and measure the response for the major peak. Calculate the quantity of C21H31N3O5 dissolved in comparison with a Standard solution having a known concentration of USP Lisinopril RS in the same medium and similarly chromatographed.
Tolerances— Not less than 80% (Q) of the labeled amount of C21H31N3O5 in the Tablets is dissolved in 30 minutes.
Uniformity of dosage units 905: meet the requirements.
Procedure for content uniformity—
Phosphate solution, Mobile phase, and Chromatographic system— Prepare as directed in the Assay.
Diluent— Dissolve 2.72 g of monobasic potassium phosphate in 800 mL of water, adjust with phosphoric acid to a pH of 4.0, dilute with water to 1000 mL, and mix.
Standard preparation— Dissolve an accurately weighed quantity of USP Lisinopril RS in Diluent to obtain a solution having a known concentration of about 0.2 mg per mL.
Test preparation— Place one Tablet in a volumetric flask of appropriate size, based on the labeled quantity, in mg, of lisinopril in the Tablet, to obtain a solution containing 0.2 mg of lisinopril per mL. Fill the flask to about 50% volume with Diluent, sonicate for 5 minutes, and shake by mechanical means for 20 minutes. Dilute with Diluent to volume, mix, and filter.
Procedure— [NOTE—Use peak areas where peak responses are indicated.] Separately inject equal volumes (about 20 µL) of the Test preparation and the Standard preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C21H31N3O5 in the Tablet taken by the formula:
(TC / D)(rU / rS),
in which T is the labeled quantity, in mg, of lisinopril in the Tablet; C is the concentration, in mg per mL, calculated on the anhydrous basis, of USP Lisinopril RS in the Standard preparation; D is the concentration, in mg per mL, of lisinopril in the Test preparation, based upon the labeled quantity per Tablet and the extent of dilution; and rU and rS are the lisinopril peak responses obtained from the Test preparation and the Standard preparation, respectively.
Related compounds—
Phosphate solution, Mobile phase, Diluent, and Chromatographic system— Prepare as directed in the Assay.
Standard solution— Dilute the Standard preparation, prepared as directed in the Assay, with Diluent to obtain a solution having a known concentration of about 20 µg per mL.
Test solution— Use the Assay preparation.
Procedure— Proceed as directed in the Assay. Measure the responses of the lisinopril peak obtained from the Standard solution, and of all peaks other than that of lisinopril obtained from the Test solution. Calculate the percentage of related compounds in each Tablet taken by the formula:
100(V / 10)(C / L)(rU / rS),
in which V is the volume, in mL, of the Test solution; C is the concentration, in mg per mL, calculated on the anhydrous basis, of USP Lisinopril RS in the Standard solution; L is the quantity, in mg, of lisinopril in each Tablet, taken as determined in the Assay; rU is the sum of all peak responses other than that of lisinopril obtained from the Test solution; and rS is the lisinopril peak response obtained from the Standard solution: not more than 2.0%, calculated on the basis of the quantity, in mg, of lisinopril in the portion of Tablets taken, as determined in the Assay, is found.
Residual solvents 467: meet the requirements.
(Official January 1, 2007)
Assay—
Phosphate solution— Dissolve 4.1 g of monobasic potassium phosphate in about 900 mL of water in a 1000-mL volumetric flask, and adjust with phosphoric acid to a pH of 2.0. Dilute with water to volume, and mix.
Mobile phase— Dissolve 1.0 g of sodium 1-hexanesulfonate in 800 mL of Phosphate solution. Add 200 mL of acetonitrile, mix, filter, and degas. Make adjustments if necessary (see System Suitability under Chromatography 621).
Diluent— Prepare a mixture of water and methanol (4:1).
Standard preparation— Dissolve an accurately weighed quantity of USP Lisinopril RS in Diluent to obtain a solution having a known concentration of about 0.2 mg per mL.
Assay preparation— Transfer to a suitable size volumetric flask 10 Tablets, which when diluted with Diluent will yield a solution having a concentration of about 0.2 mg per mL. Add Diluent, and sonicate for 5 minutes. Shake the flask by mechanical means for 20 minutes, dilute with Diluent to volume, mix, and filter.
Chromatographic system (see Chromatography 621)—The liquid chromatograph is equipped with a 215-nm detector and a 4.6-mm × 20-cm column that contains packing L7 and is maintained at a temperature of 40. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed under Procedure: the column efficiency determined from the analyte peak is not less than 850 theoretical plates, the tailing factor for the analyte peak is not more than 2.0, the capacity factor, k¢, for the analyte peak is not less than 2.0, and relative standard deviation for replicate injections is not more than 2.0%.
Procedure— [NOTE—Use peak areas where peak responses are indicated.] Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C21H31N3O5 in each Tablet taken by the formula:
(L / D)C(rU / rS),
in which L is the labeled quantity, in mg, of lisinopril in each Tablet, D is the concentration, in mg per mL, of lisinopril in the Assay preparation based on the labeled quantity per Tablet and the extent of dilution; C is the concentration, in mg per mL, calculated on the anhydrous basis, of USP Lisinopril RS in the Standard preparation; and rU and rS are the lisinopril peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Andrzej Wilk, Ph.D., Senior Scientific Associate
Expert Committee : (MDCV05) Monograph Development-Cardiovascular
USP29–NF24 Page 1263
Pharmacopeial Forum : Volume No. 31(4) Page 1090
Phone Number : 1-301-816-8305